Waters buys MOBILion to push into $2B proteomics market
What's the deal? Waters CorporationDealroom has a profile for this one. Try Dealroom → has acquired MOBILion Systems, the developer of SLIM high-resolution ion-mobility separation technology, for undisclosed terms. Waters, a life sciences and diagnostics company, said the deal broadens its entry into proteomics by pairing SLIM with its Xevo MRT mass spectrometry platform.
What's the endgame? MOBILion's SLIM technology separates molecules by size, shape, and charge in milliseconds, resolving differences that liquid chromatography and mass spectrometry struggle to distinguish alone. Waters expects the combination to increase proteome coverage, sensitivity, and throughput for complex biological samples.
Why now? Waters is targeting what it calls a $2 billion addressable market for LC-MS proteomics, growing at a high single-digit rate. It also wants data generation at the scale that AI foundation and frontier models require.
The acquisition ties into Waters AI Link, which brings AnthropicDealroom has a profile for this one. Try Dealroom →'s Model Context Protocol to the company's software, plus Waters' role in Anthropic's Model Hardware Standard research program. Together, these support "lab-in-the-loop" workflows, in which AI agents help design experiments and direct instruments.
What's the leadership saying? "Today's acquisition gives Waters a unique advantage in proteomics that will define our leadership, first in research and, over time, in the clinic," said Udit Batra, president and chief executive officer of Waters.
Longer term, Waters sees a path from biomarker discovery to clinical validation on a single platform, including blood-based screening for multi-cancer early detection and minimal residual disease monitoring.
What could go wrong? Waters disclosed no deal terms or expected financial contribution, making the acquisition's near-term significance hard to judge. Commercial adoption of the combined technology remains to be demonstrated.
The signal: Waters is buying into a fast-moving proteomics instrument race, where rivals Thermo Fisher and Bruker have both touted faster, more sensitive platforms. Adding ion-mobility separation and AI-ready workflows is Waters' bid to keep pace as the field pushes toward high-throughput, AI-enabled discovery.
Read more: prnewswire.com
Image credit: IAEA Imagebank
